Myriad Genetics Licenses Chemotherapy Management Technology from Saladax | GenomeWeb
NEW YORK (GenomeWeb News) – Myriad Genetics said today it has licensed pharmacokinetic analysis technology from Saladax Biomedical for use in chemotherapy drug management.
 
Under the agreement, Myriad has gained an exclusive North American license for Saladax technology that allows doctors to personalize chemotherapy doses to improve the efficacy of the treatment and to minimize toxicity, the company said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.